Saudi J. Med. Pub. Health **Vol. 1,** No. 2, pp 1306-1312 (2024)

Saudi Journal of Medicine and Public Health

https://saudijmph.com/index.php/pub

https://doi.org/10.64483/202412359

A Biopsychosocial-Systems Analysis of the Tuberculosis Continuum: Integrating Diagnostic Technology, Clinical Management, Health Informatics, and Social Determinants from Detection to Reintegration

Eshtyaq Hussain Assiri (1) , Ali Abdalaziz Ibrahim Alrayes (2) , Sultan Mousa Wasili (3) , Ali Mousa Nushayli (4) , Sultan Khader Al-Anzi (5) , Juhaina Ali Alaliwi (6) , Fatimah Haidar Hussein Abutalib (7) , Nora Ali Albishy (8) , Muhammed Abdulaziz Almuteri (9) , Awadh Bader Alotaibi (10) , Khalid Abdullah Mohammad Alshammari (11) , Ali Mohammed Al Amer (12)

(1) Muhayil General Hospital,Ministry of Health, Saudi Arabia,
(2) Tumair General Hospital,Ministry of Health, Saudi Arabia,
(3) Abuareash General Hospital, Ministry of Health, Saudi Arabia,
(4) Sultan Khader Al-Anzi,Ministry of Health, Saudi Arabia,
(5) King Fahad Hospital Qassim Health Cluster,Ministry of Health, Saudi Arabia,
(6) Al-Omran General Hospital,Ministry of Health, Saudi Arabia,
(7) Erada Hospital for Mental Health, Jazan,Ministry of Health, Saudi Arabia,
(8) Tuwaiq General Health Center, Riyadh,Ministry of Health, Saudi Arabia,
(9) Madinah,Ministry of Health, Saudi Arabia,
(10) Sanam Phc,Ministry of Health, Saudi Arabia,
(11) West Janadriyah Health Center,Ministry of Health, Saudi Arabia,
(12) Al Ha'ir Health Center,Ministry of Health, Saudi Arabia

Abstract

Background: Tuberculosis (TB) management is characterized by a protracted patient journey through complex, often fragmented health systems. While the biomedical cascade—from screening to treatment—is well-described, critical gaps persist at the intersections of clinical practice, health information systems, and the social ecology of illness. The integration of health informatics within this continuum remains underexplored as a pivotal mediator of care quality and patient trajectory. **Aim:** This narrative review synthesizes interdisciplinary evidence to construct an integrated model of the TB patient pathway. **Methods:** A comprehensive literature analysis was conducted across PubMed, Scopus, CINAHL, IEEE Xplore, and Sociological Abstracts (2010–2024). Search terms included tuberculosis care cascade, health information systems, electronic health records, diagnostic delay, data interoperability, social stigma, and structural vulnerability. **Results:** The analysis reveals that advances in rapid molecular diagnostics and digital radiology are frequently undermined by weak health information systems that fail to ensure timely result communication and care coordination. Nursing-led adherence support is critical but often operates without integrated patient data. Sociological factors, particularly stigma and economic precarity, function as systemic barriers exacerbated by informational gaps. Health informatics emerges not merely as a tool for surveillance but as a crucial infrastructure for linking diagnostic, clinical, and social support services. **Conclusion:** Effective TB care requires a paradigm shift toward a digitally enabled, person-centered continuum. This necessitates interoperable health information systems that unify diagnostic, therapeutic, and social data, empowering providers and patients while mitigating structural vulnerabilities. Future programs must co-design technological and social interventions to bridge the persistent divides between data, care, and context.

Keywords: tuberculosis continuum of care, health information systems, diagnostic delay, structural vulnerability, interoperability.

Introduction

Tuberculosis (TB), caused by *Mycobacterium tuberculosis*, persists as a paramount global health concern, with an estimated 10.6 million new cases and 1.3 million deaths in 2022 alone (World Health Organization [WHO], 2024). The biomedical narrative of TB—exposure, infection, latent state, active disease, treatment, and cure—belies a far more complex human reality. The patient's journey through this disease is a protracted navigation of fragmented health systems, intricate diagnostic technologies, demanding therapeutic regimens, and profound social sequelae that extend long after microbiological cure. This journey, often conceptualized as the "TB care cascade" or "patient pathway," is marked by significant attrition, or "loss

*Corresponding author e-mail: ashtyaqasiri532@gmail.com (Eshtyaq Hussain Assiri).

Receive Date: 12 December 2024, Revise Date: 30 December 2024, Accept Date: 31 December 2024

to follow-up," at nearly every stage, undermining global control efforts (Subbaraman et al., 2018).

Traditionally, TB programs and research have operated within disciplinary silos. Epidemiologists model transmission dynamics, radiologists and laboratory specialists refine diagnostic algorithms, nurses and clinicians manage treatment, and sociologists document community impacts. While this specialization drives innovation within fields, it creates a fragmented understanding of the patient experience. A patient does not encounter "epidemiology" but rather community stigma; they do not interact with "molecular diagnostics" but with a sputum sample collection process that may be shrouded in fear and confusion (Addo et al., 2022). This disconnect between technical precision and lived reality is a critical barrier to effective care.

Therefore, this narrative review proposes an integrated, interdisciplinary examination of the TB patient journey. It synthesizes evidence from 2010 to 2024 across five critical domains: epidemiology, which maps the landscape of risk and defines screening paradigms; radiology, which provides the visual evidence of disease; laboratory science, which confirms etiology and drug resistance; nursing, which orchestrates the therapeutic alliance and adherence support; and sociology and health information, which illuminates the structural violence of stigma, poverty, and gender that dictates ultimate outcomes. by viewing the pathway through this multifaceted lens, we move beyond a linear cascade of clinical tasks toward a holistic understanding of a dynamic, often chaotic, socio-clinical trajectory. This review argues that sustainable TB control is unachievable without deliberately bridging these disciplinary perspectives to design care systems that are as responsive to social vulnerability as they are to mycobacterial drug resistance.

The Epidemiological and Sociological Landscape of Suspicion and Presentation

The TB journey begins not in a clinic, but within a social and epidemiological context that profoundly influences if and when care is sought. Epidemiology identifies populations at heightened risk—including contacts of active cases, people living with HIV, migrants from high-burden countries, and those in congregate settings like prisons (Kasaie et al., 2023). However, the translation of population-level risk into individual action is mediated by sociological factors. Structural determinants—such as poverty, overcrowded housing, food insecurity, and limited access to primary healthcare—create the fertile ground for both TB transmission and diagnostic delay (Hargreaves et al., 2011). An individual's health-seeking behavior is shaped by cultural beliefs about TB's etiology, fear of diagnostic procedures, and competing economic priorities, where a day lost to clinic attendance may mean a day without wages (Sreeramareddy et al., 2014).

A critical sociological construct here is stigma. TB-associated stigma, often intertwined with HIV stigma and associations with poverty and marginalization, acts as a powerful deterrent to presentation. Fear of social isolation, loss of employment, or marital discord can lead individuals to hide symptoms, resort to informal care, or endure illness until it becomes severe and less concealable (Courtwright & Turner, 2010). This patient-initiated delay is a major contributor to the "total diagnostic delay," which includes both "patient delay" (symptom onset to first healthcare visit) and "health system delay" (first visit to diagnosis). Extended delays result in worse clinical outcomes, increased transmission within communities, and greater societal cost (Storla et al., 2008). Thus, the initial stage of the journey is a negotiation between biological symptomology and social survival, where epidemiological risk profiles are lived out through experiences of structural vulnerability.

Integration of Radiology, Laboratory, and Clinical Encounter

Once a patient enters the healthcare system, the diagnostic process represents a critical interface between technology, protocol, and human interaction. This stage is fraught with potential for further attrition (Table 1 & Figure 1).

Radiology, primarily chest radiography (CXR), serves as the most common initial triage tool. Its role is to identify abnormalities suggestive of pulmonary TB, triggering the collection of microbiological specimens. While digital CXR with computer-aided detection (CAD) software is improving screening sensitivity and objectivity, access in low-resource settings remains limited (Qin et al., 2021). For complex cases, such as drug-resistant TB (DR-TB) or extra-pulmonary disease, computed tomography (CT) offers superior characterization of parenchymal lesions, lymph nodes, and complications like bronchiectasis or cavitation. However, the radiographic picture is never pathognomonic; it must be interpreted in concert with clinical and laboratory data (Jung et al., 2023).

The laboratory confirmation cascade has been revolutionized by molecular diagnostics. The WHO-endorsed Xpert MTB/RIF and its ultra-version provide rapid detection of *M. tuberculosis* complex and rifampicin resistance directly from sputum within two hours, dramatically shortening health system delay (Dorman et al., 2018). For patients unable to produce sputum or with suspected extra-pulmonary TB, culture remains the gold standard for diagnosis and drug susceptibility testing (DST), but its utility is hampered by slow turnaround times (6-8 weeks). Newer technologies like line probe assays and targeted next-generation sequencing are accelerating DST for second-line drugs (WHO, 2024). However, these technological advances exist within a fragile pre-analytical ecosystem. The quality of the sputum sample, its storage and transport conditions, and the accuracy of patient identification and labeling are fundamental prerequisites that rely on effective nursing and administrative systems. A failed sample collection or lost result can mean a patient disappears from the cascade at this juncture (Köser et al., 2021).

This diagnostic phase is managed through a clinical encounter that requires skillful communication. Healthcare providers, often nurses or mid-level practitioners, must navigate patient anxiety, explain the need for potentially unpleasant procedures like sputum induction or lymph node aspiration, and arrange follow-up for results—all while maintaining patient trust and engagement. The efficiency of this nexus determines whether a presumptive case becomes a confirmed, notified case ready for treatment.

Table 1: The Interdisciplinary TB Patient Pathway

Stage of Pathway	Core Disciplinary Inputs	Key Actions & Technologies	Major Attrition Risks ("Leaks" in Cascade)
1. Symptom Onset & Recognition	Epidemiology, Sociology	Community awareness, symptom recognition.	Stigma, cultural beliefs, gender norms, and economic barriers to care-seeking.
2. Healthcare Seeking & Initial Assessment	Sociology, Nursing, Radiology	First clinical contact, history-taking, and Chest X-Ray (CXR).	Poor provider awareness, diagnostic overshadowing, inaccessible clinics, and cost.
3. Diagnostic Confirmation	Laboratory Science, Radiology, Nursing	Sputum collection, Xpert MTB/RIF, Culture, CT scan.	Inadequate sample, loss to follow-up before result, laboratory delay/error.
4. Treatment Initiation & Adherence	Nursing, Clinical Medicine, Sociology	Treatment prescription, Directly Observed Therapy (DOT), and adherence counseling.	Drug stock-outs, severe side effects, stigma at the DOT site, and economic hardship.
5. Treatment Completion & Cure	Nursing, Epidemiology	Follow-up monitoring, end-of-treatment sputum tests.	Premature self-discontinuation, development of DR-TB, and loss to follow-up.
6. Post-Treatment & Social Reintegration	Sociology, Nursing, Epidemiology	Economic rehabilitation, stigma mitigation, and mental health support.	Chronic pulmonary disability, continued social exclusion, and unemployment.



Figure 1: Integrated model of Tuberculosis continuum

Nursing, Adherence, and Managing the "Long Haul"

A confirmed TB diagnosis initiates the demanding therapeutic phase, where the central figure often shifts to the nurse or community health worker. Treatment for drug-susceptible TB lasts at least six months, while regimens for DR-TB can extend to 20 months or more with more toxic drug combinations. Sustained adherence is the single greatest predictor of individual cure and prevention of drug resistance (Kruk et al., 2018).

Nursing science provides the framework for adherence support. The historically dominant model is Directly Observed Therapy (DOT), where a healthcare worker or community volunteer watches the patient ingest each dose. While DOT aims to ensure completion, its rigid application has been critiqued as paternalistic and inconvenient for patients. A more patient-centered approach, supported self-administered therapy, combined with education, counseling, and tools like pill calendars or digital medication reminders, can be equally effective and more empowering (Karangwa & van de Watt, 2022). The nurse's role expands into side-effect management, a critical component for retention. Nausea, hepatotoxicity, arthralgia, and psychiatric effects can be debilitating. Proactive monitoring, symptomatic relief, and clear communication about what to expect build therapeutic alliance and prevent treatment interruption (Sant´ Anna et al., 2023).

However, adherence does not occur in a clinical vacuum. It is a sociological phenomenon. The "social determinants of adherence" include: the financial cost of travel to clinics; the fear of being seen at a TB clinic and identified as a patient; the need to migrate for work; and gendered caregiving responsibilities that may deprioritize a woman's own health (Daftary et al., 2018). Effective nursing, therefore, requires intersectional competence—the ability to assess not just pill-taking, but the social context in which those pills must be taken. This may involve coordinating social support, food packages, or transportation vouchers, activities that lie at the intersection of clinical care and social work.

Sociological and Clinical Dimensions of Reintegration

The endpoint of the biomedical cascade is "treatment success" (cure or completion). Yet, for many survivors, this marks the beginning of a new, challenging phase: social and physical reintegration. The sociological impact of TB is often long-lasting and severe.

Post-TB sequelae are common. A significant proportion of survivors are left with chronic respiratory impairment, reduced lung function, and persistent cough, limiting their capacity for physical labor—the primary livelihood for many in high-burden settings (Allwood et al., 2021). This creates a direct pathway from biological illness to economic disability. Mental health consequences, including depression and anxiety related to the trauma of illness and treatment, are frequently unaddressed (Sweetland et al., 2017).

Most profound is the persistence of stigma and social exclusion. Even after cure, individuals may be labeled as "former TB patients," facing discrimination in marriage, employment, and community participation. The fear of this "spoiled identity" can deter others from seeking care, creating a vicious cycle (Daftary, 2012). Gender disparities are acute; women may face abandonment or divorce, while men may be rendered unable to fulfill breadwinner roles, leading to profound psychological distress (Chidambaram et al., 2021). Successful reintegration, therefore, requires interventions that go far beyond clinical follow-up, encompassing livelihood training, legal aid, mental health services, and community-level anti-stigma campaigns.

Table 2: An Interdisciplinary Framework for a Patient-Centered TB Program

Program Component	Biomedical/Technical Focus	Sociological/Structural Focus	Required Interdisciplinary Collaboration
Case Finding & Screening	High-sensitivity CXR/CAD, Xpert MTB/RIF.	Community-based mobile units; stigma-free messaging; engagement of community leaders.	Epidemiology, Radiology, Sociology, Community Health.
Diagnostic Pathway	Optimized lab networks, rapid transport, quality-assured cultures.	Patient navigation support; pre-test counseling; financial/transport support for diagnostics.	Laboratory Science, Nursing, Sociology.
Treatment Initiation & Support	DR-TB regimens, side-effect management protocols.	Choice of DOT location (home/clinic); adherence packages (food, transport); peer support groups.	Nursing, Clinical Medicine, Sociology.
Monitoring & Evaluation	Sputum conversion, treatment outcome reporting.	Tracking social outcomes (employment, stigma); patient-reported experience measures (PREMs).	Epidemiology, Nursing, Sociology.
Post-Treatment Support	Assessment for chronic lung disease.	Livelihood programs, legal counseling, mental health services, and community reintegration initiatives.	Sociology, Nursing, Respiratory Medicine.

Health Informatics as an Enabler and Barrier

The seamless progression of a patient through the TB continuum is fundamentally dependent on the flow of information. **Health informatics**—the intersection of information science, computer science, and healthcare—provides the critical infrastructure for this flow, yet it often represents a significant point of system failure (Blaya et al., 2010). Effective TB management relies on a complex data ecosystem encompassing laboratory information management systems (LIMS), radiology picture archiving and communication systems (PACS), electronic health records (EHRs), pharmacy databases, and national TB surveillance registries (Manyazewal et al., 2021).

The informatics journey mirrors the clinical one. At the point of **diagnostic testing**, the accurate linkage of a patient identifier to a sputum sample or radiographic image is paramount. Barcoding systems and digital linkages between point-of-care testing devices (e.g., GeneXpert) and central databases can minimize pre-analytical errors and lost results (Köser et al., 2021). However, in many high-burden settings, paper-based request forms and manual data entry persist, creating bottlenecks and errors that delay diagnosis and treatment initiation (Deriel et al., 2018).

Following confirmation, **treatment initiation and monitoring** demand reliable data on drug regimens, dispensing, and adherence. Digital adherence technologies (DATs), such as smart pill boxes with cellular connectivity or video-supported directly observed therapy (vDOT), generate real-time adherence data that can alert nurses to potential defaults (Subbaraman et al., 2018). These tools, when integrated into a patient's EHR, allow for proactive, personalized adherence support. However, most DATs operate as standalone "siloed" applications, with data rarely flowing into the primary clinical record, limiting their utility for comprehensive care coordination (Ngwatu et al., 2018).

A core challenge is the pervasive lack of **interoperability**—the ability of different information systems to exchange, interpret, and use data cohesively. The radiologist's report may reside in a separate PACS, the molecular test result in the laboratory's LIMS, and the nurse's encounter notes in a paper register, forcing clinicians to mentally synthesize disparate data points (Brenas et al., 2017). This fragmentation increases cognitive load, heightens the risk of missed information, and impedes continuity of care, especially during referrals between primary clinics, hospitals, and DR-TB centers.

Furthermore, **surveillance and program management** rely on aggregated data from these systems to monitor epidemiological trends, drug resistance patterns, and program performance indicators like treatment success rates. Timely, accurate data is essential for resource allocation and policy-making. Yet, the burden of duplicate data entry into parallel paper and digital systems contributes to healthcare worker burnout and compromises data quality (Siyam et al., 2021). Ultimately, weaknesses in health informatics infrastructure do not merely create administrative inefficiency; they directly propagate the very delays and losses within the care cascade that perpetuate TB transmission and mortality.

Synthesis and Conclusion

The patient journey through tuberculosis represents a profound traverse across interconnected biological, technological, clinical, and social landscapes. This interdisciplinary analysis elucidates a critical, systemic truth: the technical brilliance of a rapid molecular assay is profoundly dimmed if its result cannot reliably reach the treating nurse; the dedication of a community health worker is hamstrung without actionable data on a patient's underlying social vulnerabilities; and the biomedical promise of cure remains hollow if survivors confront a lifetime of social stigma and economic disability. Consequently, the traditional, linear "cascade of care" model—which charts a simplistic progression from diagnosis to treatment completion—functions as an insufficient heuristic for a challenge of such multifaceted complexity. Its linearity fails to capture the recursive feedback loops, where social setbacks trigger clinical attrition, and informational gaps exacerbate both.

We must therefore advocate for a fundamental paradigm shift toward a **digitally-augmented, person-centered TB continuum**. This model envisions a cohesive, adaptive ecosystem where interoperability forms the core operational principle. First, **robust health information systems** must serve as the foundational backbone, seamlessly connecting data from epidemiological screening, digital radiology, laboratory information systems, pharmacy dispensaries, and clinical encounters (Pellison et al., 2020). This technical interoperability enables a unified, longitudinal patient record that travels with the individual across care settings, breaking down the silos that currently fragment responsibility and insight. Second, **nursing and community health practice** must be actively empowered by this integrated data stream. Clinical decision support, configured to generate alerts for missed doses, flags for emerging social risk factors, and automated prompts for crucial follow-up tests, can transform care management from a reactive to a proactive and predictive endeavor. This shifts the role of the health worker from a mere tracker of patients to a supported analyst and intervenor.

Third, this integrated system must make **sociological vulnerabilities** legible and actionable within the clinical workflow. By ethically documenting structured indicators of poverty, food insecurity, housing instability, and experienced stigma within electronic health records, care packages and social support interventions can be targeted with precision (Craig et al., 2017). This approach formally recognizes social determinants not as peripheral concerns but as core clinical variables requiring assessment and management. Fourth, **patients** must be engaged as co-managers through accessible, human-centered digital tools. Patient portals for viewing diagnostic results, confidential SMS medication reminders, and secure platforms for reporting symptoms or drug side-effects foster a sense of agency and strengthen the therapeutic alliance, moving beyond passive adherence to active partnership (Hassane-Harouna et al., 2023).

Achieving this vision necessitates moving beyond a naive technological determinism that assumes digital tools alone will rectify systemic flaws. It demands **participatory co-design** with frontline health workers, TB survivors, and affected communities to ensure that systems are usable, useful, contextually appropriate, and equitable (Westgard & Fleming, 2020). This must be coupled with sustained investment in digital infrastructure, data governance frameworks, and comprehensive workforce training, positioned with parity alongside investments in medical commodities. Ultimately, the fight to end TB in the 21st century is inextricably linked to the strength and intelligence of our health information ecosystems. By deliberately intertwining the lenses of diagnostic technology, clinical care, health informatics, and sociological insight, we can forge a continuum that does not merely process patients but sustains people, restoring not just health but the fundamental dignity and opportunity stolen by disease.

References

1. Addo, J., Pearce, D., Metcalf, M., Lundquist, C., Thomas, G., Barros-Aguirre, D., ... & Strange, M. (2022). Living with tuberculosis: a qualitative study of patients' experiences with disease and treatment. *BMC Public Health*, *22*(1), 1717. https://doi.org/10.1186/s12889-022-14115-7
2. Allwood, B. W., Byrne, A., Meghji, J., Rachow, A., Van Der Zalm, M. M., & Schoch, O. D. (2021). Post-tuberculosis lung disease: clinical review of an under-recognised global challenge. *Respiration*, *100*(8), 751-763. https://doi.org/10.1159/000512531
3. Blaya, J. A., Fraser, H. S., & Holt, B. (2010). E-health technologies show promise in developing countries. *Health affairs*, *29*(2), 244-251. https://doi.org/10.1377/hlthaff.2009.0894
4. Brenas, J. H., Al-Manir, M. S., Baker, C. J., & Shaban-Nejad, A. (2017). A malaria analytics framework to support evolution and interoperability of global health surveillance systems. *IEEE Access*, *5*, 21605-21619.
5. Chidambaram, V., Tun, N. L., Majella, M. G., Ruelas Castillo, J., Ayeh, S. K., Kumar, A., ... & Karakousis, P. C. (2021). Male sex is associated with worse microbiological and clinical outcomes following tuberculosis treatment: a retrospective cohort study, a systematic review of the literature, and meta-analysis. *Clinical Infectious Diseases*, *73*(9), 1580-1588. https://doi.org/10.1093/cid/ciab527
6. Courtwright, A., & Turner, A. N. (2010). Tuberculosis and stigmatization: pathways and interventions. *Public health reports*, *125*(4_suppl), 34-42. https://doi.org/10.1177/00333549101250S407
7. Craig, G. M., Daftary, A., Engel, N., O'driscoll, S., & Ioannaki, A. (2017). Tuberculosis stigma as a social determinant of health: a systematic mapping review of research in low incidence countries. *International Journal of Infectious Diseases*, *56*, 90-100. https://doi.org/10.1016/j.ijid.2016.10.011
8. Daftary, A. (2012). HIV and tuberculosis: the construction and management of double stigma. *Social science & medicine*, *74*(10), 1512-1519. https://doi.org/10.1016/j.socscimed.2012.01.027
9. Daftary, A., Mitchell, E. M., Reid, M. J., Fekadu, E., & Goosby, E. (2018). To end TB, first-ever high-level meeting on tuberculosis must address stigma. *The American Journal of Tropical Medicine and Hygiene*, *99*(5), 1114. https://doi.org/10.4269/ajtmh.18-0591
10. Dorman, S. E., Schumacher, S. G., Alland, D., Nabeta, P., Armstrong, D. T., King, B., ... & Xie, Y. (2018). Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. *The Lancet infectious diseases*, *18*(1), 76-84. https://doi.org/10.1016/S1473-3099(17)30691-6
11. Deriel, E., Puttkammer, N., Hyppolite, N., Diallo, J., Wagner, S., Honoré, J. G., ... & Barnhart, S. (2018). Success factors for implementing and sustaining a mature electronic medical record in a low-resource setting: a case study of iSanté in Haiti. *Health policy and planning*, *33*(2), 237-246. https://doi.org/10.1093/heapol/czx171
12. Hargreaves, J. R., Boccia, D., Evans, C. A., Adato, M., Petticrew, M., & Porter, J. D. (2011). The social determinants of tuberculosis: from evidence to action. *American journal of public health*, *101*(4), 654-662. https://doi.org/10.2105/AJPH.2010.199505
13. Hassane-Harouna, S., Gils, T., Decroo, T., Ortuño-Gutiérrez, N., Delamou, A., Cherif, G. F., ... & de Jong, B. C. (2023). Community-supported self-administered tuberculosis treatment combined with active tuberculosis screening: a pilot experience in Conakry, Guinea. *Global Health Action*, *16*(1), 2262134. https://doi.org/10.1080/16549716.2023.2262134
14. Jung, M. K., Lee, S. Y., Min, E. J., & Ko, J. M. (2023). CT scan differences of pulmonary TB according to presence of pleural effusion. *Chest*, *164*(6), 1387-1395. https://doi.org/10.1016/j.chest.2023.06.043
15. Kasaie, P., Pennington, J., Gupta, A., Dowdy, D. W., & Kendall, E. A. (2023). Trials underestimate the impact of preventive treatment for household contacts exposed to multidrug-resistant tuberculosis: a simulation study. *medRxiv*, 2023-02. https://doi.org/10.1101/2023.02.06.23285528
16. Köser, C. U., Robledo, J., Shubladze, N., Schön, T., Dolinger, D. L., & Salfinger, M.

(2021). Guidance is needed to mitigate the consequences of analytic errors during antimicrobial susceptibility testing for TB. *The International Journal of Tuberculosis and Lung Disease*, *25*(10), 791-794. https://doi.org/10.5588/ijtld.21.0428

17. Kruk, M. E., Gage, A. D., Arsenault, C., Jordan, K., Leslie, H. H., Roder-DeWan, S., ... & Pate, M. (2018). High-quality health systems in the Sustainable Development Goals era: time for a revolution. *The Lancet global health*, *6*(11), e1196-e1252. https://doi.org/10.1016/S2214-109X(18)30386-3
18. Manyazewal, T., Woldeamanuel, Y., Blumberg, H. M., Fekadu, A., & Marconi, V. C. (2021). The potential use of digital health technologies in the African context: a systematic review of evidence from Ethiopia. *NPJ digital medicine*, *4*(1), 125. https://doi.org/10.1038/s41746-021-00487-4
19. Ngwatu, B. K., Nsengiyumva, N. P., Oxlade, O., Mappin-Kasirer, B., Nguyen, N. L., Jaramillo, E., ... & Yassin, M. (2018). The impact of digital health technologies on tuberculosis treatment: a systematic review. *European Respiratory Journal*, *51*(1). https://doi.org/10.1183/13993003.01596-2017
20. Pellison, F. C., Rijo, R. P. C. L., Lima, V. C., Crepaldi, N. Y., Bernardi, F. A., Galliez, R. M., ... & Alves, D. (2020). Data integration in the Brazilian Public Health System for Tuberculosis: use of the semantic web to establish interoperability. *JMIR Medical Informatics*, *8*(7), e17176. https://doi.org/10.2196/17176
21. Qin, Z. Z., Barrett, R., Ahmed, S., Sarker, M. S., Paul, K., Adel, A. S. S., ... & Creswell, J. (2022). Comparing different versions of computer-aided detection products when reading chest X-rays for tuberculosis. *PLOS Digital Health*, *1*(6), e0000067. https://doi.org/10.1371/journal.pdig.0000067
22. Sant´ Anna, F. M., Araújo-Pereira, M., Schmaltz, C. A., Arriaga, M. B., Andrade, B. B., & Rolla, V. C. (2023). Impact of adverse drug reactions on the outcomes of tuberculosis treatment. *PLoS One*, *18*(2), e0269765. https://doi.org/10.1371/journal.pone.0269765
23. Siyam, A., Ir, P., York, D., Antwi, J., Amponsah, F., Rambique, O., ... & O'Neill, K. (2021). The burden of recording and reporting health data in primary health care facilities in five low-and lower-middle income countries. *BMC health services research*, *21*(Suppl 1), 691. https://doi.org/10.1186/s12913-021-06652-5
24. Sreeramareddy, C. T., Qin, Z. Z., Satyanarayana, S., Subbaraman, R., & Pai, M. (2014). Delays in diagnosis and treatment of pulmonary tuberculosis in India: a systematic review. *The International Journal of Tuberculosis and Lung Disease*, *18*(3), 255-266. https://doi.org/10.5588/ijtld.13.0585
25. Storla, D. G., Yimer, S., & Bjune, G. A. (2008). A systematic review of delay in the diagnosis and treatment of tuberculosis. *BMC public health*, *8*(1), 15. https://doi.org/10.1186/1471-2458-8-15
26. Subbaraman, R., de Mondesert, L., Musiimenta, A., Pai, M., Mayer, K. H., Thomas, B. E., & Haberer, J. (2018). Digital adherence technologies for the management of tuberculosis therapy: mapping the landscape and research priorities. *BMJ global health*, *3*(5), e001018. https://doi.org/10.1136/bmjgh-2018-001018
27. Sweetland, A. C., Kritski, A., Oquendo, M. A., Sublette, M. E., Norcini Pala, A., Silva, L. R., ... & Wainberg, M. L. (2017). Addressing the tuberculosis–depression syndemic to end the tuberculosis epidemic. *The International Journal of Tuberculosis and Lung Disease*, *21*(8), 852-861. https://doi.org/10.5588/ijtld.16.0584
28. Westgard, C., & Fleming, W. O. (2020). The use of implementation science tools to design, implement, and monitor a community-based mHealth intervention for child health in the Amazon. *Frontiers in public health*, *8*, 411. https://doi.org/10.3389/fpubh.2020.00411
29. World Health Organization. (2024). *WHO consolidated guidelines on tuberculosis. Module 3: diagnosis–rapid diagnostics for tuberculosis detection*. World Health Organization.
30. World Health Organization, & World Health Organization Staff. (2013). *Global tuberculosis report 2013*. World health organization.